1.	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAUY922A2101, 2006-002766-20, NCT00526045
2.	Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NU 10L01, STU00038215, NCT01259089
3.	A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAUY922A2206, 2010-020116-11, NCT01124864
4.	Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAUY922A2109, 2009-015628-27, NCT01271920
5.	Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAUY922A1101, NCT01132625
6.	A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SCRI GI 143, NCT01226732
7.	89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition Phase: No phase specified Type: Biomarker/Laboratory analysis Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 27112008 version 1, 2008-005751-26, NCT01081600